Schizotypal Personality Disorder Clinical Trial
Official title:
Guanfacine Enhancement of Working Memory: Prospects for Augmenting Cognitive Remediation in the Schizophrenia Spectrum
This is a study to assess the efficacy augmenting cognitive remediation therapy (CRT) with a pharmacological agent for individuals with schizotypal personality disorder (SPD). Impaired cognition, along with functional and social skill deficits, is a core feature of schizophrenia and schizophrenia spectrum disorders. A better understanding of the cognitive and functional impairments in schizophrenia-related conditions, as well as the identification of interventions that can reduce these impairments, are vital to improving outcomes for individual with these disorders.
This study proposes to 1) evaluate the effects of 7.5 weeks of twice weekly cognitive
remediation sessions, combined with concurrent administration of 8 weeks of
guanfacine/placebo, on performance on cognitive, functional, and social skills performance
measures in a sample of SPD patients with proven deficits in these areas. 2) Compare the
effect of cognitive remediation therapy + 8 weeks guanfacine with cognitive remediation
therapy + placebo on cognition in this schizophrenia spectrum disorder population. 3)
Further characterize cognitive impairment in SPD using specific tests of working memory to
evaluate the relationship between working memory and functional and social skill outcomes in
this population.
The study hypothesizes that:
1. While both groups (those receiving CRT + guanfacine or CRT +placebo) will demonstrate
improvements in overall cognitive functioning, SPD participants receiving CRT +
guanfacine will evidence greater increases in post-treatment performance on our primary
outcome measures—MATRICS battery total score, AX-CPT, N-Back, PASAT and DOT Test—
particularly in areas related to working memory.
2. Participants receiving CRT + guanfacine will also demonstrate greater improvements in
functional and social functioning exploratory measures, as evidenced by performance on
our secondary assessments, the UPSA, SSPA, MASC, and Reading of the Mind in the Eyes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02149823 -
Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
|
Phase 1 | |
Terminated |
NCT00353379 -
Pharmacology of Cognition in Schizotypal Personality Disorder
|
Phase 4 | |
Recruiting |
NCT05710926 -
Evolutionary Systems Therapy for Schizotypy
|
N/A | |
Recruiting |
NCT00252044 -
Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder
|
N/A | |
Completed |
NCT00158028 -
Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder
|
N/A | |
Completed |
NCT02800681 -
Psychopathological Differences Between Asperger Syndrome and Schizotypal Disorder in an Adult Sample
|
||
Recruiting |
NCT01466205 -
Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder
|
Phase 2 | |
Completed |
NCT02535156 -
Schizotypal Personality Disorder Risperidone
|
Phase 1/Phase 2 | |
Completed |
NCT04764708 -
Compassion and Metacognition in Schizotypal Personality
|
N/A | |
Completed |
NCT02507206 -
A D1 Agonist For Working Memory
|
Phase 2 |